Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Changes in rumen microbiota of cows in response to dietary supplementation with nitrate, linseed and saponin alone or in combination.

Popova M, Guyader J, Silberberg M, Seradj AR, Saro C, Bernard A, Gérard C, Martin C, Morgavi DP.

Appl Environ Microbiol. 2018 Nov 30. pii: AEM.02657-18. doi: 10.1128/AEM.02657-18. [Epub ahead of print]

PMID:
30504215
2.

Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease.

Taxonera C, Ponferrada Á, Riestra S, Bermejo F, Saro C, Martín-Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, López-Serrano P, Barrio J, Suarez C, Iglesias E, Argüelles-Arias F, Ferrer I, Marín-Jiménez I, Hernández-Camba A, Bastida G, Van Domselaar M, Martínez-Montiel P, Olivares D, Rivero M, Fernandez-Salazar L, Nantes Ó, Merino O, Alba C, Gisbert JP; CONVERT study group from GETECCU .

J Crohns Colitis. 2018 Nov 15;12(11):1270-1279. doi: 10.1093/ecco-jcc/jjy104.

PMID:
30052856
3.

Effectiveness of Interventions to Modulate the Rumen Microbiota Composition and Function in Pre-ruminant and Ruminant Lambs.

Saro C, Hohenester UM, Bernard M, Lagrée M, Martin C, Doreau M, Boudra H, Popova M, Morgavi DP.

Front Microbiol. 2018 Jun 18;9:1273. doi: 10.3389/fmicb.2018.01273. eCollection 2018.

4.

Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study).

Marín-Jiménez I, Saro C, Díaz V, Acosta MB, Gómez-García M, Casbas AG.

Drugs Context. 2018 Mar 6;7:212505. doi: 10.7573/dic.212505. eCollection 2018.

5.

Comparison of automated ribosomal intergenic spacer analysis (ARISA) and denaturing gradient gel electrophoresis (DGGE) techniques for analysing the influence of diet on ruminal bacterial diversity.

Saro C, Molina-Alcaide E, Abecia L, Ranilla MJ, Carro MD.

Arch Anim Nutr. 2018 Apr;72(2):85-99. doi: 10.1080/1745039X.2018.1429135. Epub 2018 Jan 30.

PMID:
29381103
6.

Shifts in microbial populations in Rusitec fermenters as affected by the type of diet and impact of the method for estimating microbial growth (15N v. microbial DNA).

Mateos I, Ranilla MJ, Saro C, Carro MD.

Animal. 2017 Nov;11(11):1939-1948. doi: 10.1017/S1751731117000878. Epub 2017 May 2.

PMID:
28462771
7.

Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.

Taxonera C, Ponferrada Á, Bermejo F, Riestra S, Saro C, Martín-Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, López-Serrano P, Barrio J, Suarez C, Iglesias E, Argüelles-Arias F, Ferrer I, Marín-Jiménez I, Hernández-Camba A, Bastida G, Van Domselaar M, Martínez-Montiel P, Olivares D, Alba C, Gisbert JP; SEGURTB study group from GETECCU.

J Crohns Colitis. 2017 Jul 1;11(7):792-800. doi: 10.1093/ecco-jcc/jjx022.

PMID:
28333182
8.

Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab.

Saro C, Ceballos D, Muñoz F, de la Coba C, Aguilar MD, Lázaro P, García-Sánchez V, Hernández M, Barrio J, de Francisco R, Fernández LI, Barreiro-de Acosta M.

Rev Esp Enferm Dig. 2017 Feb;109(2):122-129. doi: 10.17235/reed.2016.4600/2016.

9.

Risk factors for tuberculosis in inflammatory bowel disease: anti-tumor necrosis factor and hospitalization.

Riestra S, de Francisco R, Arias-Guillén M, Saro C, García-Alvarado M, Duque JM, Palacios JJ, Muñoz F, Blanco L, Castaño O, Pérez-Martínez I, Martínez-Camblor P, Pérez Hernández D, Suárez A.

Rev Esp Enferm Dig. 2016 Sep;108(9):541-9. doi: 10.17235/reed.2016.4440/2016.

10.

Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent.

R-Grau Mdel C, Chaparro M, Mesonero F, Barreiro-de Acosta M, Castro L, Castro M, Domènech E, Mancenido N, Pérez-Calle JL, Taxonera C, Barrio J, De Francisco R, Fernández-Salgado E, Luzón L, Merino O, Oltra L, Saro C, Bermejo F, García-Sánchez V, Ginard D, Gutiérrez A, Vera I, Antón R, Ber Y, Calvet X, Gisbert JP.

Dig Liver Dis. 2016 Jun;48(6):613-9. doi: 10.1016/j.dld.2016.02.012. Epub 2016 Mar 2.

PMID:
26992847
11.

Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease.

Taxonera C, Barreiro-de-Acosta M, Bastida G, Martinez-Gonzalez J, Merino O, García-Sánchez V, Gisbert JP, Marín-Jiménez I, López-Serrano P, Gómez-García M, Iglesias E, Lopez-Sanroman A, Chaparro M, Saro C, Bermejo F, Pérez-Carazo L, Plaza R, Olivares D, Alba C, Mendoza JL, Fernández-Blanco I.

J Crohns Colitis. 2016 Jun;10(6):657-62. doi: 10.1093/ecco-jcc/jjw016. Epub 2016 Jan 19.

PMID:
26786982
12.

Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.

Taxonera C, Barreiro-de Acosta M, Calvo M, Saro C, Bastida G, Martín-Arranz MD, Gisbert JP, García-Sánchez V, Marín-Jiménez I, Bermejo F, Chaparro M, Ponferrada Á, Martínez-Montiel MP, Pajares R, de Gracia C, Olivares D, Alba C, Mendoza JL, Fernández-Blanco I.

Dig Dis Sci. 2015 Oct;60(10):3075-84. doi: 10.1007/s10620-015-3735-4. Epub 2015 Jun 5.

PMID:
26044830
13.

Resources Utilization and Costs the Year Before and After Starting Treatment with Adalimumab in Crohn's Disease Patients.

Saro C, Ceballos D, Muñoz F, De la Coba C, Aguilar MD, Lázaro P, Iglesias-Flores E, Barreiro-de Acosta M, Hernández-Durán MD, Barrio J, Riestra S, Fernández Salazar L; EFICADEC Researchers Group.

Inflamm Bowel Dis. 2015 Jul;21(7):1631-40. doi: 10.1097/MIB.0000000000000413.

PMID:
25961910
14.

Identification of risk loci for Crohn's disease phenotypes using a genome-wide association study.

Alonso A, Domènech E, Julià A, Panés J, García-Sánchez V, Mateu PN, Gutiérrez A, Gomollón F, Mendoza JL, Garcia-Planella E, Barreiro-de Acosta M, Muñoz F, Vera M, Saro C, Esteve M, Andreu M, Chaparro M, Manyé J, Cabré E, López-Lasanta M, Tortosa R, Gelpí JL, García-Montero AC, Bertranpetit J, Absher D, Myers RM, Marsal S, Gisbert JP.

Gastroenterology. 2015 Apr;148(4):794-805. doi: 10.1053/j.gastro.2014.12.030. Epub 2014 Dec 31.

PMID:
25557950
15.

Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy.

Castaño-Milla C, Chaparro M, Saro C, Barreiro-de Acosta M, García-Albert AM, Bujanda L, Martín-Arranz MD, Carpio D, Muñoz F, Manceñido N, García-Planella E, Piqueras M, Calvet X, Cabriada JL, Botella B, Bermejo F, Gisbert JP.

J Clin Gastroenterol. 2015 Jan;49(1):34-40. doi: 10.1097/MCG.0000000000000169.

PMID:
25485513
16.

Technical note: Comparison of automated ribosomal intergenic spacer analysis and denaturing gradient gel electrophoresis to assess bacterial diversity in the rumen of sheep.

Saro C, Ranilla MJ, Cifuentes A, Rosselló-Mora R, Carro MD.

J Anim Sci. 2014 Mar;92(3):1083-8. doi: 10.2527/jas.2013-7175. Epub 2014 Feb 3.

PMID:
24492564
17.

Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.

Chaparro M, Ordás I, Cabré E, Garcia-Sanchez V, Bastida G, Peñalva M, Gomollón F, García-Planella E, Merino O, Gutiérrez A, Esteve M, Márquez L, Garcia-Sepulcre M, Hinojosa J, Vera I, Muñoz F, Mendoza JL, Cabriada JL, Montoro MA, Barreiro-de Acosta M, Ceña G, Saro C, Aldeguer X, Barrio J, Maté J, Gisbert JP.

Inflamm Bowel Dis. 2013 Jun;19(7):1404-10. doi: 10.1097/MIB.0b013e318281f28f.

PMID:
23665964
18.

Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.

Casanova MJ, Chaparro M, Domènech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, Gomollón F, Rodrigo L, Calvet X, Esteve M, García-Planella E, García-López S, Taxonera C, Calvo M, López M, Ginard D, Gómez-García M, Garrido E, Pérez-Calle JL, Beltrán B, Piqueras M, Saro C, Botella B, Dueñas C, Ponferrada A, Mañosa M, García-Sánchez V, Maté J, Gisbert JP.

Am J Gastroenterol. 2013 Mar;108(3):433-40. doi: 10.1038/ajg.2012.430. Epub 2013 Jan 15.

PMID:
23318480
19.
20.

A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300.

Julià A, Domènech E, Ricart E, Tortosa R, García-Sánchez V, Gisbert JP, Nos Mateu P, Gutiérrez A, Gomollón F, Mendoza JL, Garcia-Planella E, Barreiro-de Acosta M, Muñoz F, Vera M, Saro C, Esteve M, Andreu M, Alonso A, López-Lasanta M, Codó L, Gelpí JL, García-Montero AC, Bertranpetit J, Absher D, Panés J, Marsal S.

Gut. 2013 Oct;62(10):1440-5. doi: 10.1136/gutjnl-2012-302865. Epub 2012 Aug 30.

PMID:
22936669
21.

[Of what value is improved accessibility without good treatment outcome?].

Akerlund B, Gerok-Andersson K, Saro C.

Lakartidningen. 2011 Aug 10-23;108(32-33):1477. Swedish. No abstract available.

PMID:
21922937
22.

Long-term durability of response to adalimumab in Crohn's disease.

Chaparro M, Panés J, García V, Merino O, Nos P, Domènech E, Peñalva M, García-Planella E, Esteve M, Hinojosa J, Andreu M, Muñoz F, Gutiérrez A, Mendoza JL, Barrio J, Barreiro-de M, Vera I, Vilar P, Cabriada JL, Montoro MA, Aldeguer X, Saro C, Gisbert JP.

Inflamm Bowel Dis. 2012 Apr;18(4):685-90. doi: 10.1002/ibd.21758. Epub 2011 May 25.

PMID:
21618353
23.

Comparative analysis of the expression of metalloproteases and their inhibitors in resected crohn's disease and complicated diverticular disease.

Altadill A, Eiró N, González LO, Junquera S, González-Quintana JM, Sánchez MR, Andicoechea A, Saro C, Rodrigo L, Vizoso FJ.

Inflamm Bowel Dis. 2012 Jan;18(1):120-30. doi: 10.1002/ibd.21682. Epub 2011 Mar 15.

PMID:
21438097
24.

Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.

Taxonera C, Estellés J, Fernández-Blanco I, Merino O, Marín-Jiménez I, Barreiro-de Acosta M, Saro C, García-Sánchez V, Gento E, Bastida G, Gisbert JP, Vera I, Martinez-Montiel P, Garcia-Morán S, Sánchez MC, Mendoza JL.

Aliment Pharmacol Ther. 2011 Feb;33(3):340-8. doi: 10.1111/j.1365-2036.2010.04531.x. Epub 2010 Dec 7.

25.
26.

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.

Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, Esteve M; REPENTINA study; GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group.

Gut. 2010 Oct;59(10):1340-6. doi: 10.1136/gut.2010.208413. Epub 2010 Jun 24.

PMID:
20577000
28.

Evaluation of procedures for detaching particle-associated microbes from forage and concentrate incubated in Rusitec fermenters: efficiency of recovery and representativeness of microbial isolates.

Martínez ME, Ranilla MJ, Ramos S, Tejido ML, Saro C, Carro MD.

J Anim Sci. 2009 Jun;87(6):2064-72. doi: 10.2527/jas.2008-1634. Epub 2009 Feb 27.

PMID:
19251933
29.

[Recommendations for patients with Crohn's disease starting treatment with adalimumab: a rapid guide].

Cabriada JL, García Sánchez V, Gomollón F, Hinojosa J, López San Román A, Mendoza JL, Mínguez M, Ricart E, Saro C.

Gastroenterol Hepatol. 2008 Dec;31(10):693-7. doi: 10.1016/S0210-5705(08)75817-5. Epub 2009 Jan 7. Spanish. No abstract available.

PMID:
19174086
30.

Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study.

Loras C, Saro C, Gonzalez-Huix F, Mínguez M, Merino O, Gisbert JP, Barrio J, Bernal A, Gutiérrez A, Piqueras M, Calvet X, Andreu M, Abad A, Ginard D, Bujanda L, Panés J, Torres M, Fernández-Bañares F, Viver JM, Esteve M; GETECCu (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa).

Am J Gastroenterol. 2009 Jan;104(1):57-63. doi: 10.1038/ajg.2008.4. Erratum in: Am J Gastroenterol. 2009 Mar;104(3):801. Boadas, Jaume [added]; Ortiz, Jordi [added]; Galter, Sara [added].

PMID:
19098850
31.

Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy.

Zabana Y, Domènech E, San Román AL, Beltrán B, Cabriada JL, Saro C, Araméndiz R, Ginard D, Hinojosa J, Gisbert JP, Mañosa M, Cabré E, Gassull MA.

Inflamm Bowel Dis. 2008 Oct;14(10):1387-91. doi: 10.1002/ibd.20496.

PMID:
18452206
32.

Surgical treatment of hallux valgus and forefoot deformities in Sweden: a population-based study.

Saro C, Bengtsson AS, Lindgren U, Adami J, Blomqvist P, Felländer-Tsai L.

Foot Ankle Int. 2008 Mar;29(3):298-304. doi: 10.3113/FAI.2008.0298.

PMID:
18348826
33.

Resource use in patients with Crohn's disease treated with infliximab.

Saro C, da la Coba C, Casado MA, Morales JM, Otero B.

Aliment Pharmacol Ther. 2007 Nov 15;26(10):1313-23. Epub 2007 Sep 7.

34.

Outcome after distal metatarsal osteotomy for hallux valgus: a prospective randomized controlled trial of two methods.

Saro C, Andrén B, Wildemyr Z, Felländer-Tsai L.

Foot Ankle Int. 2007 Jul;28(7):778-87.

PMID:
17666169
35.

Quality-of-life outcome after hallux valgus surgery.

Saro C, Jensen I, Lindgren U, Felländer-Tsai L.

Qual Life Res. 2007 Jun;16(5):731-8. Epub 2007 Mar 7.

PMID:
17342454
36.

Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.

Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, Ceballos D, Peñate M, Gassull MA; Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis.

Aliment Pharmacol Ther. 2007 Feb 15;25(4):409-18.

37.

[Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease].

Cabriada JL, Doménech E, Gomollón F, González-Carro P, González-Lara V, Hinojosa J, Jiménez-López CE, Nos P, Obrador A, Panès J, Saro C, Varea V, Lafuente R, Guilera M.

Gastroenterol Hepatol. 2006 Feb;29(2):85-92. Spanish. No abstract available.

PMID:
16448611
38.

Reliability of radiological and cosmetic measurements in hallux valgus.

Saro C, Johnson DN, Martinez De Aragón J, Lindgren U, Felländer-Tsai L.

Acta Radiol. 2005 Dec;46(8):843-51.

PMID:
16392609
39.

Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.

Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA; Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU).

Aliment Pharmacol Ther. 2004 Dec;20(11-12):1347-52.

40.

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.

Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM.

Gut. 2004 Sep;53(9):1363-5.

41.

TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease.

González S, Rodrigo L, Martínez-Borra J, López-Vázquez A, Fuentes D, Niño P, Cadahía V, Saro C, Dieguez MA, López-Larrea C.

Am J Gastroenterol. 2003 May;98(5):1101-6.

PMID:
12809834
42.

Serological markers of hepatitis A, B and C in first year student nurses.

Suárez A, Viejo G, Navascués CA, García R, Díaz G, Otero L, Saro C, Román FJ.

Rev Esp Enferm Dig. 1998 Jul;90(7):480-6. Review. English, Spanish.

PMID:
9741205
43.

[The prevalence of hepatitis A, B and C viral markers in the population of Gijón between 26 and 65 years old].

Suárez A, Viejo G, Navascués CA, García R, Díaz G, Saro C, Román FJ.

Gastroenterol Hepatol. 1997 Aug-Sep;20(7):347-52. Spanish.

PMID:
9377232
44.

Ankle arthroscopy under local and general anaesthesia for diagnostic evaluation and treatment.

Rolf C, Saro C, Engström B, Wredmark T, Movin T, Karlsson J.

Scand J Med Sci Sports. 1996 Aug;6(4):255-8.

PMID:
8896100
45.

[The prevalence of markers for the hepatitis A and B viruses in the population of Gijón between 6 and 25 years old].

Suárez A, Navascués CA, García R, Peredo B, Miguel D, Menéndez MT, Saro C, Román F.

Med Clin (Barc). 1996 Apr 6;106(13):491-4. Spanish.

PMID:
8992130
46.

[Campylobacter fetus, an infrequent microbe, as a cause of spontaneous bacterial peritonitis in cirrhosis].

Saro C, García R, Suárez A, Román FJ, Rodríguez A, Navascues CA.

Rev Esp Enferm Dig. 1994 Nov;86(5):845-7. Spanish.

PMID:
7848698
47.

[Ascitic peritonitis due to Candida albicans].

Suárez A, Otero L, Navascués CA, Menéndez MT, Román FJ, García R, Saro C, Rodríguez A.

Rev Esp Enferm Dig. 1994 Sep;86(3):691-3. Review. Spanish.

PMID:
7986605
48.

[Outbreak of acute cholestatic hepatitis A in a family. An occurrence to be prevented].

Menéndez MT, Peredo MB, Saro C, Suárez A.

Aten Primaria. 1994 Apr 15;13(6):334. Spanish. No abstract available.

PMID:
8204790

Supplemental Content

Support Center